Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19
| Autor: | Amer Hamadé, Jonathan Tousch, Pierre Michel, Golnaz Obringer, Nathalie Buschenrieder, Marjolaine Talbot, Dominique Stephan, Mahdi Issa, Naouel Bensalah, Bastien Woehl, Michèle Lehn-Hogg, Lucas Jambert |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
2019-20 coronavirus outbreak medicine.medical_specialty Demographics Coronavirus disease 2019 (COVID-19) medicine.drug_class Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) MEDLINE Low molecular weight heparin Specialties of internal medicine 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans In patient Letters to the Editor Pandemics Transaminases Aged Retrospective Studies Venous Thrombosis Hepatology business.industry SARS-CoV-2 Incidence (epidemiology) Incidence COVID-19 Retrospective cohort study Aminotransferases disorders General Medicine Venous Thromboembolism medicine.disease Venous thrombosis RC581-951 030220 oncology & carcinogenesis Oral anticoagulant 030211 gastroenterology & hepatology Original Article Female France business Venous thromboembolism Elevated AST and ALT Biomarkers Direct oral anticoagulant Liver disorders |
| Zdroj: | Annals of Hepatology Annals of Hepatology, Vol 21, Iss, Pp 100274-(2021) Annals of Hepatology, Vol 23, Iss, Pp 100306-(2021) |
| ISSN: | 1665-2681 |
| Popis: | Introduction and objectives Since the outbreak of the COVID-19 pandemic, increasing evidence suggests that infected patients present a high incidence of venous thromboembolic (VTE) events and elevated aminotransferases (AT).The objective of this work was to evaluate the incidence of aminotransferases disorders in patients infected with COVID-19 and to manage the VTE events associated with elevated AT. Patients or Materials and methods We report a retrospective study of 46 patients admitted for COVID-19 infection. Venous duplex ultrasound of lower limbs was performed in all patients at Day 0 and Day 5. All patients had antithrombotic-prophylaxis upon admission using low molecular weight heparin with Enoxaparin. Demographics, comorbidities and laboratory parameters were collected and analyzed. Results Elevated AT were reported in 28 patients (61%). 10 had acute VTE events of which eight (17.4%) had aminotransferases disorders. They had been treated with curative Enoxaparin. After a follow-up of 15 and/or 30 days, six of them were controlled, and treated with direct oral anticoagulant (DOACs) after normalization of aminotransferases. Conclusions The incidence of aminotransferases disorders associated with acute VTE events in patients infected with COVID-19 is significant. The use of DOACs appear pertinent in these patients. Monitoring of the liver balance should therefore be considered at a distance from the acute episode in the perspective of DOACs relay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|